» Articles » PMID: 10647155

Sensitivity of Anulus Fibrosus Cells to Interleukin 1 Beta. Comparison with Articular Chondrocytes

Overview
Specialty Orthopedics
Date 2000 Jan 27
PMID 10647155
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Study Design: Anulus fibrosus cells from rabbits were grown in primary culture 1) to study their ability to produce prostaglandin E2 and Type II phospholipase A2, and to express stromelysin-1 messenger ribonucleic acid; and 2) to study the effect of interleukin 1 beta on this production and on proteoglycan aggregation.

Objectives: To investigate the potency of anulus fibrosus cells to respond to interleukin 1 beta by producing degradative and inflammatory agents as compared with the potency of articular chondrocytes in the same animal.

Summary Of Background Data: Interleukin 1 beta has been implicated in the degradation of intervertebral discs. The way anulus fibrosus cells differ from articular chondrocytes in their responses to interleukin 1 beta remains to be established.

Methods: Anulus fibrosus cells and articular chondrocytes were obtained from young rabbits, grown in primary culture, and incubated with interleukin 1 beta. The newly synthesized proteoglycan was measured by labeling with [35S]-sulfate. Proteoglycan aggregation was analyzed by the elution profile on Sepharose 2B columns. The contents of collagen Type II and stromelysin-1 messenger ribonucleic acid were assessed by Northern blot analysis. The Type II phospholipase A2 activity was measured using a fluorometric substrate. Prostaglandin E2 production was evaluated by radioimmunoassay.

Results: Anulus fibrosus cells had 2.5-fold less Type II collagen messenger ribonucleic acid than articular chondrocytes, and interleukin 1 beta had no significant effect on this. Anulus fibrosus cells synthesized and secreted four-fold less proteoglycan than articular chondrocytes. Interleukin 1 beta reduced the anulus fibrosus content of total [35S]-sulfated proteoglycan by 35% (P < 0.01), and that of articular cells by 41% and decreased proteoglycan aggregation. Interleukin 1 beta induced the production of stromelysin-1 messenger ribonucleic acid in both cell types. The stromelysin-1 messenger ribonucleic acid content of anulus fibrosus cells was one half that of articular cells. Interleukin 1 beta increased the production of prostaglandin E2 and caused a dose-dependent secretion of Type II phospholipase A2 activity in both cell types. Its effect was 2.5-fold lower in anulus fibrosus cells than in articular chondrocytes.

Conclusion: Anulus fibrosus cells can be stimulated by interleukin 1 beta to produce factors implicated in local degradative and inflammatory processes. This production is associated with decreased proteoglycan aggregation. Anulus fibrosus cells respond slightly less well to interleukin 1 beta in vitro than do articular cells.

Citing Articles

Intervertebral disc degeneration and inflammatory microenvironment: expression, pathology, and therapeutic strategies.

Chen X, Wang Z, Deng R, Yan H, Liu X, Kang R Inflamm Res. 2023; 72(9):1811-1828.

PMID: 37665342 DOI: 10.1007/s00011-023-01784-2.


Regulatory Effect of Inflammatory Mediators in Intervertebral Disc Degeneration.

Li Z, Yang H, Hai Y, Cheng Y Mediators Inflamm. 2023; 2023:6210885.

PMID: 37101594 PMC: 10125773. DOI: 10.1155/2023/6210885.


IL-1Ra deficiency accelerates intervertebral disc degeneration in C57BL6J mice.

Swamy G, Salo P, Duncan N, Jirik F, Matyas J JOR Spine. 2022; 5(2):e1201.

PMID: 35783913 PMC: 9238285. DOI: 10.1002/jsp2.1201.


The role of single nucleotide polymorphisms of -889C>T (rs1800587), -238G>A (rs361525), and (rs731236) on susceptibility to herniated nucleus pulposus: a systematic review and meta-analysis.

Azharuddin A, Ilmawan M, Fajar J, Fahriani M, Mamada S, Maliga H F1000Res. 2021; 10:419.

PMID: 34504685 PMC: 8406444. DOI: 10.12688/f1000research.53235.3.


Can Implementation of Genetics and Pharmacogenomics Improve Treatment of Chronic Low Back Pain?.

Suntsov V, Jovanovic F, Knezevic E, Candido K, Knezevic N Pharmaceutics. 2020; 12(9).

PMID: 32967120 PMC: 7558486. DOI: 10.3390/pharmaceutics12090894.